Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 7Phase 1/2 3Phase EARLY_PHASE1 2

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × MART-1 Antigen × Clear all
NCT00074230 2015-05-12

Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

University Hospital Erlangen

Phase 1/2 Completed
82 enrolled
Dermatologic

Melanoma

NCT00002952 2013-09-05

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

University of Chicago

Phase 1/2 Completed
20 enrolled
Dermatologic

Melanoma

NCT00019214 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1/2 Completed
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡